OMG!! Do We Really Need All TheseAntihypertensives?? Traditional vs. Natural Therapies. Kristen Luttenberger MSN, RN, CCRN-CMC, PCCN, APN-c

Similar documents
JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Hypertension JNC 8 (2014)

Managing Hypertension in 2016

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Long-Term Care Updates

Preventing and Treating High Blood Pressure

Hypertension (JNC-8)

Modern Management of Hypertension

Modern Management of Hypertension: Where Do We Draw the Line?

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Difficult to Treat Hypertension

Update on Current Trends in Hypertension Management

Speaker Disclosure. Pharmacist Objectives. Path to New Hypertension (HTN) Guidelines. Overview of New HTN Guidelines 8/21/2014

Hypertension Update Clinical Controversies Regarding Age and Race

Clinical Review & Education. Special Communication

Management of High Blood Pressure in Adults

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology

Objectives. Describe results and implications of recent landmark hypertension trials

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

What in the World is Functional Medicine?

Recent Hypertension Guidelines

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Jared Moore, MD, FACP

What s In the New Hypertension Guidelines?

First line treatment of primary hypertension

Using the New Hypertension Guidelines

Aquifer Hypertension Guidelines Module

Treatment of Hypertension

By Prof. Khaled El-Rabat

ADVANCES IN MANAGEMENT OF HYPERTENSION

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Supplementary Online Content

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Don t let the pressure get to you:

Dr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.

ADVANCES IN MANAGEMENT OF HYPERTENSION

2017 High Blood Pressure Clinical Practice Guideline

Clinical cases with Coversyl 10 mg

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension Management: A Moving Target

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Peer Review Report. [Fixed Dose Combination Lisinopril + Hydrochlothiazide]

Hypertension Update. Aaron J. Friedberg, MD

Hypertension Management Controversies in the Elderly Patient

The JNC 8 Guidelines: A Clinical Review

2014 HYPERTENSION GUIDELINES

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Don t let the pressure get to you:

Heart Failure Clinician Guide JANUARY 2018

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES

STANDARD treatment algorithm mmHg

Physician/Clinic Collaborative Practice Agreement

Heart Failure Clinician Guide JANUARY 2016

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Effective Date: TBD Version: 1.0 (Revised: 6/11/2014)

Hypertension Update Background

ABSTRACT. Special Communication February 5, 2014

Hypertension Pharmacotherapy: A Practical Approach

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

2. Measurement Specifications 3. Patient Messaging 4. Provider Messaging Other Recent Guidelines

Executive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009

Renal Disease through the Ages: From Childbearing years to Old Age. Dr Elizabeth Jarvis, Renal Physician, General Physician, Obstetric Physician.

Summary of recommendations

ABSTRACT KEYWORDS: The prevalence of hypertension varies from percentages in all

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Clinical Recommendations: Patients with Periodontitis

Layered Approaches to Studying Drug Responses

Transcription:

OMG!! Do We Really Need All TheseAntihypertensives?? Traditional vs. Natural Therapies Kristen Luttenberger MSN, RN, CCRN-CMC, PCCN, APN-c

Hypertension Defined as persistently elevated pressure in the arteries at or above 140/90mmHg Asymptomatic Primary (90-95%) or Secondary Has been shown to be a major risk factor for: Hypertensive Heart Disease Coronary Artery Disease Stroke Aortic Aneurysm Peripheral Artery Disease Chronic Kidney Disease

Pathophysiology http://en.wikipedia.org/wiki/hypertension#/media/file:mean_arterial_pressure.png

2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults-JNC8 Grade A-Strong Recommendation Grade B-Moderate Recommendation Grade C-Weak Recommendation Grade D-Recommendation Against Grade E-Expert Opinion Grade N-No recommendation for or against

Recommendation 1 In the general population >60 yrs., initiate pharmacologic treatment to lower BP at >150 systolic or >90 diastolic. Treat to goal <150/90 mmhg. Grade A Strong

Recommendation 2 In the general population <60 yrs., initiate pharmacologic treatment to lower BP at DBP>90 mmhg and treat to a goal DBP<90 Ages 30-59 Strong Grade A Ages 18-29 Expert Opinion E

Recommendation 3 In the general population <60yrs., initiate pharmacologic treatment to lower BP at SBP>140mmHg and treat to a goal SBP<140mmHg Grade E-Expert Opinion

Recommendation 4 In the population >18 yrs., with chronic kidney disease (CKD) initiate pharmacologic treatment to lower BP at SBP>140 or DBP>90mmHg and treat to goal <140/90 mmhg. Expert Opinion-Grade E

Recommendation 5 In the population >18 yrs. with diabetes, initiate pharmacologic treatment to lower BP at SBP>140 mmhg or DBP >90and treat to a goal SBP<140mmHg and DBP<90mmHg Expert Opinion-Grade E

Recommendation 6 In the general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), angiotensinconverting enzyme inhibitor (ACE1), or angiotensin receptor blocker (ARB). Moderate Recommendation-Grade B

Recommendation 7 In the general black population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic or CCB General black population-grade B Moderate Black patients with diabetes-grade C Weak

Recommendation 8 In the population >18 yrs. with CKD, initial (or add on) antihypertensive treatment should include an ACEI or ARB to improve kidney outcomes. This applies to all CKD patients with hypertension regardless of race or diabetes status Moderate Recommendation-Grade B

Recommendation 9 If BP is not reached within a month of treatment, increase the dose of the initial drug or add a second drug from one of the classes in recommendation 6. Ongoing assessment until goal BP is reached. May add up to 3 from list then move to other drug class. No ACEI and ARB together. Expert Opinion-Grade E

ACE Inhibitors pril Angiotensin Receptor blockers sartan Captopril 50mg Enalapril 5mg Lisinopril 10mg Eprosartan 400mg Candesartan 4mg Losartan 50mg Valsartan 40-80mg Irbesartan 75mg

colorado.edu

Calcium Channel Blockers Target Dose in RCTs Amlodipine 2.5mg 10mg Diltizem ER 120-180mg 360mg Nitrendipine 10mg 20mg

Peripheral and coronary vasodilation Depression of cardiac contractility Depression of SA node Depression of AV node Nifedipine +++++ + + 0 Diltiazem +++ ++ +++++ ++++ Verapamil ++++ ++++ +++++ +++++ http://pharmacologycorner.com/calcium-channel-blockers-classification-mechanism-of-action-indications/

Thiazide-type diuretics Target Dose in RCTs Bendroflumethiazide 5mg 10mg Chorthalidone 12.5mg 12.5-25mg Hydroclorothizide 12.5-25mg 25-100mg Indapamide 1.25mg 1.25-2.5mg

Each diuretic targets specific segments in the nephron http://group14.pbworks.com/w/page/16025091/diuretics

Healthy Living Quotes in JN8 For all persons with hypertension, the potential benefits of a healthy diet, weight control, and regular exercise cannot be overemphasized These lifestyle treatments have the potential to improve BP control and even reduce medication needs Although the authors of this hypertension guideline did not conduct an evidence review of lifestyle treatments in patients taking and not taking antihypertensive medication, we support the recommendation of the 2013 Lifestyle Work Group

2013 AHA Lifestyle Management Guideline DASH dietary pattern - Grade A Lower sodium intake - Grade A Aerobic physical activity - Grade B

http://www.1800dietplan.com/wp-content/uploads/2010/09/dash.jpg

Sodium No more than 2,400mg/day Further restriction to 1,500mg/day is further associated with greater reduction in BP or Reduce daily intake by 1,000mg/day even if target is not achieved yet http://media.salon.com/2013/05/shutterstock_98345939-1280x960.jpg

http://www.disabled-world.com/disabled/uploads/1/electrolytes.gif There is insufficient evidence from RCTs to determine whether reducing sodium intake plus changing dietary intake of any other single mineral (K, Ca, Mg) lowers BP more than reducing sodium intake alone.

Aerobic Physical Activity 3-4 sessions/week lasting 40 minutes per session Must involve moderatevigorous intensity physical activity http://davidlasnier.com/wp-content/uploads/2012/08/richard-simmons.jpg

YOGA 10 Studies met inclusion criteria First research done in US was at UPENN in 2008 RCTs, quasi-experimental, & pilot studies Reduces BP, glucose levels, cholesterol levels, body weight http://thelimetreeyoga.com/wp-content/uploads/2014/04/sample-yoga-2.jpg

Relaxation Therapies http://www.katimorton.com/wp-content/uploads/2013/07/relax-600x300.jpg

Hibiscus sabdariffa L. (Sour Tea) http://g04.a.alicdn.com/kf/ut8dz1axmpaxxagofbx2/201550983/ut8dz1axmpaxxagofbx2.jpg

Qi gong http://centeracupuncture.com/wp-content/uploads/2010/11/qi_gong1.jpg

Melatonin http://www.koshervitamins.com/images/images_101/pictures/solgar_melatonin_10mg_tabs.jpg http://thetreatmentherbs.com/wp-content/uploads/2014/08/lynn_sleep.jpeg

Folic Acid

Garlic http://www.cancats.net/wp-content/uploads/2014/07/garlic-bulbs.jpg

Eicosapentaenoic Acid Docosahexaenoic Acid https://www.helpmeoutdoc.com/wp-content/uploads/2014/10/omega3.jpg https://missrosen.files.wordpress.com/2012/02/waves.jpg

CoEnzyme Q10 http://dgchaacicgqa5.cloudfront.net/wp-content/uploads/2011/08/antioxidants3.jpg

Dietary Supplements & Hypertension Precautions Evidence for Dietary Supplements is frequently limited and meager quality Plant based preparations may contain numerous compounds with a myriad of unknown effects Factors may alter the quantity and quality of the active ingredient Dietary Supplements do not require FDA approval thereby are not held to the same standard in regards to safety and efficacy

How do I know what I m taking?? http://kalatas.com.au/wp-content/uploads/2013/02/folic-acid.jpg http://wellgal.com/wp-content/uploads/2013/10/bottles-of-omega-3-supplements.jpg http://www.wholefoodsmagazine.com/sites/default/files/images/articles/2013/jan uary/certifications%20logos/usp.jpg

In Summary Despite the medical knowledge, hypertension in this country is not well controlled Adverse events and the complexity of antihypertensive therapy tends to decrease adherence There is good evidence that complementary and alternative medicines/therapies help with the control of blood pressure primarily or as adjunctive therapy; but the studies need to get better There is evidence that just a mild reduction of 5-6mmHg in blood pressure cuts the risk of stroke by 40%, heart disease by 15%, and overall mortality 7% (Law et al., 2009)

References DeSimone, M. E., & Crowe, A. (2009). Nonpharmacological approaches in the management of hypertension. Journal of the American Academy of Nurse Practitioners, 21(4), 189-196. Dickinson, H. O., Beyer, F. R., Ford, G. A., Nicolson, D., Campbell, F., Cook, J. V., & Mason, J. (2008). Relaxation therapies for the management of primary hypertension in adults. The Cochrane Library. Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Miller, N. H., Hubbard, V. S.,... & Yanovski, S. Z. (2014). 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(25_PA), 2960-2984. Grossman, E., Laudon, M., & Zisapel, N. (2011). Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular health and risk management, 7, 577. Hulin, I., Duris, I., Paulis, L., Sapakova, E., & Mravec, B. (2009). Dangerous versus useful hypertension (A holistic view of hypertension). European journal of internal medicine, 20(2), 226-230. James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J.,... & Ortiz, E. (2014). 2014 evidencebased guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama, 311(5), 507-520. Lee, M. S., Pittler, M. H., Guo, R., & Ernst, E. (2007). Qigong for hypertension: a systematic review of randomized clinical trials. Journal of hypertension, 25(8), 1525-1532. Miller, P. E., Van Elswyk, M., & Alexander, D. D. (2014). Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. American journal of hypertension, 27(7), 885-896. McRae, M. P. (2009). High-dose folic acid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials. Journal of chiropractic medicine, 8(1), 15-24. Okonta, N. R. (2012). Does yoga therapy reduce blood pressure in patients with hypertension?: an integrative review. Holistic nursing practice, 26(3), 137-141. Rasmussen, C. B., Glisson, J. K., & Minor, D. S. (2012). Dietary supplements and hypertension: potential benefits and precautions. The Journal of Clinical Hypertension, 14(7), 467-471. Rosenfeldt, F. L., Haas, S. J., Krum, H., Hadj, A., Ng, K., Leong, J., & Watts, G. F. (2007). Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of human hypertension, 21(4), 297-306.

References Serban, C., Sahebkar, A., Ursoniu, S., Andrica, F., & Banach, M. (2015). Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Journal of hypertension, 33(6), 1119-1127. Xiong, X. J., Wang, P. Q., Li, S. J., Li, X. K., Zhang, Y. Q., & Wang, J. (2015). Garlic for hypertension: A systematic review and metaanalysis of randomized controlled trials. Phytomedicine, 22(3), 352-361.